Idiopathic Pulmonary Fibrosis
Conditions
Brief summary
To gain further insight on the characteristics, management, disease progression and the outcomes of patients with IPF, as diagnosed and treated under real-world, clinical practice conditions in Greece. More specifically, this registry will be used to: Provide a comprehensive clinical picture of IPF, Track access to health care and cost of caring for IPF patients over time, Examine the implementation of treatment guidelines used on patients diagnosed with IPF, according to the existing diagnosis guidelines, Characterization of patients on different treatments. To provide information regarding survival and mortality causes, IPF exacerbations as well as IPF patient co-morbidities including myocardial infarction, CNS infarction, other arterial thromboembolic events, deep vein thrombosis, hemorrhage, gastrointestinal perforation and pulmonary hypertension. Data regarding IPF patient hospitalization will be collected and evaluated with regards to potential respiratory causes, and there will be documentation of treatment patterns and economic aspects. Patients will be followed up for 2 years and information regarding IPF treatment changes since the last visit will be collected.
Detailed description
Purpose: To gain further knowledge on the characteristics, management, progression and outcomes of patients with IPF as treated under real-world, clinical practice conditions in Greece Study Design: National, multi-center, observational disease registry based on new data from a significant sample size of IPF patients in Greece. Patients will be followed up for 2 years and information will be collected during this time period. This is a non-interventional study and primary data collected during study visits will be used
Interventions
None listed
Sponsors
Boehringer Ingelheim
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Newly diagnosed (less than 6 months) or patients previously diagnosed with IPF (more than 6 months from baseline visit), based upon the consensus statement jointly issued by ATS/ERS/JRS/ALAT in 2011 (see Annexes 6 and 7 for HRCT and histological criteria in Annex 6) * Exclusion of other known causes of ILD (e.g., domestic and occupational environmental exposures, connective tissue disease, and drug toxicity) * Assessment of IPF based on HRCT or combinations of HRCT and surgical lung biopsy, if available * Age =40 years old at the time of inclusion * Written informed consent for participation in the registry * Patients that can be followed up further, during the scheduled study period
Exclusion criteria
* Expected lung transplantation within the following 6 months * Participation in clinical trials
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib | From signing the informed consent onwards until the end of the study, up to 24 months. | Number of patients in each category with usage of pirfenidone and nintedanib is reported. The categories for usage of pirfenidone and nintedanib are the following: * Yes * No * Unknown * Missing |
| Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | At baseline visit and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit. | Number in each category of non-pharmacological treatment (e.g. start of Long-term oxygen therapy (LTOT), new listing for lung transplantation, physiotherapy) for Idiopathic Pulmonary Fibrosis (IPF) by study visit is reported. The categories of non-pharmacological treatment for Idiopathic Pulmonary Fibrosis (IPF) are the following: * No * Yes * Unknown * Missing |
| Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | At baseline (up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit. | Number of patients in each category of physician's clinical assessment of the probable course of IPF by study visit is reported. Physician's clinical rating of the probable course of IPF (stable, slow or rapid progression) was based on available Forced vital capacity (FVC) results, diffusion capacity for carbon monoxide (DLCO) results, physical examination, hospitalizations/events between the visits. The categories of physician's clinical assessment are the following: * Stable disease * Slow progression * Rapid progression * No judgement possible * Missing |
| Number of Physician Contacts Per Patient by Study Visit | At baseline (up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit. | Number of physician contacts per patient is reported. For the baseline visit mean and standard deviation of physician contacts with the patient up to 12 months prior to baseline visit is reported. For the study visits at 3 months, at 6 months, at 12 months, at 18 months and at 24 months mean and standard deviation of physician contacts with the patient since the last study visit is reported. |
| Number of Visits in Outpatient Department by Study Visit | At baseline (up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit. | Number of visits in outpatient department by study visit is reported. For the baseline visit mean and standard deviation of visits in outpatient department up to 12 months prior to baseline visit is reported. For the study visits at 3 months, at 6 months, at 12 months, at 18 months and at 24 months mean and standard deviation of visits in outpatient department since the last study visit is reported. |
| Number of Visits in Pulmonologists by Study Visit | At baseline (up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit. | Number of visits in pulmonologists by study visit is reported. For the baseline visit mean and standard deviation of visits in pulmonologists up to 12 months prior to baseline visit is reported. For the study visits at 3 months, at 6 months, at 12 months, at 18 months and at 24 months mean and standard deviation of visits in pulmonologists since the last study visit is reported. |
| Number of Visits in Other Physicians Than the Pulmonologists by Study Visit | At baseline (up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit. | Number of visits in other physicians than the pulmonologists by study visit is reported. For the baseline visit mean and standard deviation of visits in other physicians than the pulmonologists up to 12 months prior to baseline visit is reported. For the study visits at 3 months, at 6 months, at 12 months, at 18 months and at 24 months mean and standard deviation of visits in other physicians than the pulmonologists since the last study visit is reported. |
| Number of Idiopathic Pulmonary Fibrosis (IPF) Related Procedures by Study Visit | At baseline (up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit. | Number of Idiopathic Pulmonary Fibrosis (IPF) related procedures by study visit is reported. For the baseline visit mean and standard deviation of Idiopathic Pulmonary Fibrosis (IPF) related procedures up to 12 months prior to baseline visit is reported. For the study visits at 3 months, at 6 months, at 12 months, at 18 months and at 24 months mean and standard deviation of Idiopathic Pulmonary Fibrosis (IPF) related procedures since the last study visit is reported. |
| Number of Patients in Each Category of Hospitalizations by Study Visit | At baseline up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit. | Number of patients in each category of hospitalizations by study visit is reported. For the baseline visit number of patients in each category of hospitalizations up to 12 months prior to baseline visit is reported. For the study visits at 3 months, at 6 months, at 12 months, at 18 months and at 24 months number of patients in each category of hospitalizations since the last study visit is reported. The categories of hospitalization were: * No * Yes * Unknown * Missing |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients in Each Category of Concomitant Medications | From signing the informed consent onwards until the end of the study, up to 24 months. | Concomitant medication was defined as any treatment presented following the Informed Consent Form (ICF) signature. If stop date was missing in the electronic Case Report Form (eCRF), medication was considered as concomitant. The number of patients in each category of the following concomitant medications is reported. The concomitant medications are: * Corticosteroids * N-Acetylcysteine * Azathioprine * Cyclophosphamide * Cyclosporine A * Other immuno-suppressant * Anticoagulants * Gastroesophageal reflux disease (GERD) medication * Phosphodiesterase type 5 (PDE-5) inhibitor * Endothelin receptor antagonist * Non-steroidal anti-inflammatory drugs (NSAIDs) other than aspirin * Hormonal contraceptives * Hormone replacement therapy * Anti-vascular endothelial growth factor (VEGF) drugs * Other (other than listed above) The categories for each concomitant medication listed above are the following: * Yes * No * Unknown * Missing |
Countries
Greece
Participant flow
Recruitment details
This was a national, multi -center, observational disease and outcomes registry study based on new data from a significant sample size of Greek idiopathic pulmonary fibrosis (IPF) patients.
Pre-assignment details
All subjects were screened for eligibility prior to participation in the trial. Subjects attended a specialist site which ensured that they (the subjects) strictly met all inclusion and none of the exclusion criteria. Subjects were not to be allocated to a treatment group if any of the entry criteria were violated.
Participants by arm
| Arm | Count |
|---|---|
| IPF Patients With Less Than 6 Months Diagnosis Patients in Greece diagnosed less than 6 months (newly diagnosed) with Idiopathic Pulmonary Fibrosis (IPF) from the study baseline visit. | 96 |
| IPF Patients With Equal or More Than 6 Months Diagnosis Patients in Greece diagnosed since 6 or more months with Idiopathic Pulmonary Fibrosis (IPF) from the study baseline visit. | 205 |
| Total | 301 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 10 | 45 |
| Overall Study | Reason unknown | 22 | 35 |
Baseline characteristics
| Characteristic | IPF Patients With Equal or More Than 6 Months Diagnosis | Total | IPF Patients With Less Than 6 Months Diagnosis |
|---|---|---|---|
| Age, Continuous | 70.8 Years STANDARD_DEVIATION 7.87 | 71.6 Years STANDARD_DEVIATION 7.75 | 73.4 Years STANDARD_DEVIATION 7.27 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 205 Participants | 301 Participants | 96 Participants |
| Sex: Female, Male Female | 37 Participants | 55 Participants | 18 Participants |
| Sex: Female, Male Male | 168 Participants | 246 Participants | 78 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 10 / 96 | 45 / 205 |
| other Total, other adverse events | 10 / 96 | 21 / 205 |
| serious Total, serious adverse events | 7 / 96 | 22 / 205 |
Outcome results
Primary
Number of Idiopathic Pulmonary Fibrosis (IPF) Related Procedures by Study Visit
Number of Idiopathic Pulmonary Fibrosis (IPF) related procedures by study visit is reported. For the baseline visit mean and standard deviation of Idiopathic Pulmonary Fibrosis (IPF) related procedures up to 12 months prior to baseline visit is reported. For the study visits at 3 months, at 6 months, at 12 months, at 18 months and at 24 months mean and standard deviation of Idiopathic Pulmonary Fibrosis (IPF) related procedures since the last study visit is reported.
Time frame: At baseline (up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit.
Population: Full Analysis Set (FAS) comprised all subjects enrolled in the study with at least one measurement of any of the primary endpoints during the study. This population was used to run any statistics of the study. Only participants with non-missing results are reported.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| IPF Patients With Less Than 6 Months Diagnosis | Number of Idiopathic Pulmonary Fibrosis (IPF) Related Procedures by Study Visit | Baseline (up to 12 months prior to baseline visit) | 2.638 IPF related procedures per patient | Standard Deviation 1.067 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Idiopathic Pulmonary Fibrosis (IPF) Related Procedures by Study Visit | 3 months (since last visit) | 1.216 IPF related procedures per patient | Standard Deviation 1.015 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Idiopathic Pulmonary Fibrosis (IPF) Related Procedures by Study Visit | 6 months (since last visit) | 1.271 IPF related procedures per patient | Standard Deviation 1.026 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Idiopathic Pulmonary Fibrosis (IPF) Related Procedures by Study Visit | 12 months (since last visit) | 1.722 IPF related procedures per patient | Standard Deviation 1.241 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Idiopathic Pulmonary Fibrosis (IPF) Related Procedures by Study Visit | 18 months (since last visit) | 1.613 IPF related procedures per patient | Standard Deviation 1.27 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Idiopathic Pulmonary Fibrosis (IPF) Related Procedures by Study Visit | 24 months (since last visit) | 1.569 IPF related procedures per patient | Standard Deviation 1.345 |
Primary
Number of Patients in Each Category of Hospitalizations by Study Visit
Number of patients in each category of hospitalizations by study visit is reported. For the baseline visit number of patients in each category of hospitalizations up to 12 months prior to baseline visit is reported. For the study visits at 3 months, at 6 months, at 12 months, at 18 months and at 24 months number of patients in each category of hospitalizations since the last study visit is reported. The categories of hospitalization were: * No * Yes * Unknown * Missing
Time frame: At baseline up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit.
Population: Full Analysis Set (FAS) comprised all subjects enrolled in the study with at least one measurement of any of the primary endpoints during the study. This population was used to run any statistics of the study.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 12 months (since last visit) | No | 73 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 3 months (since last visit) | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 12 months (since last visit) | Yes | 3 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | Baseline (up to 12 months prior to baseline visit) | Yes | 13 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 12 months (since last visit) | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 3 months (since last visit) | Missing | 10 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 12 months (since last visit) | Missing | 20 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | Baseline (up to 12 months prior to baseline visit) | Missing | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 18 months (since last visit) | No | 72 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 6 months (since last visit) | No | 80 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 18 months (since last visit) | Yes | 1 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 3 months (since last visit) | No | 85 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 18 months (since last visit) | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 6 months (since last visit) | Yes | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 18 months (since last visit) | Missing | 23 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | Baseline (up to 12 months prior to baseline visit) | No | 83 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 24 months (since last visit) | No | 62 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 6 months (since last visit) | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 24 months (since last visit) | Yes | 2 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 3 months (since last visit) | Yes | 1 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 24 months (since last visit) | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 6 months (since last visit) | Missing | 16 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 24 months (since last visit) | Missing | 32 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | Baseline (up to 12 months prior to baseline visit) | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 24 months (since last visit) | Missing | 80 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | Baseline (up to 12 months prior to baseline visit) | No | 183 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | Baseline (up to 12 months prior to baseline visit) | Yes | 22 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | Baseline (up to 12 months prior to baseline visit) | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 3 months (since last visit) | No | 169 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 3 months (since last visit) | Yes | 5 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 3 months (since last visit) | Unknown | 1 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 3 months (since last visit) | Missing | 30 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 6 months (since last visit) | No | 162 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 6 months (since last visit) | Yes | 7 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 6 months (since last visit) | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 6 months (since last visit) | Missing | 36 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 12 months (since last visit) | No | 152 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 12 months (since last visit) | Yes | 9 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 12 months (since last visit) | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 12 months (since last visit) | Missing | 44 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 18 months (since last visit) | No | 132 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 18 months (since last visit) | Yes | 8 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 18 months (since last visit) | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 18 months (since last visit) | Missing | 65 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 24 months (since last visit) | No | 120 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 24 months (since last visit) | Yes | 5 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | 24 months (since last visit) | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Hospitalizations by Study Visit | Baseline (up to 12 months prior to baseline visit) | Missing | 0 Participants |
Primary
Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit
Number in each category of non-pharmacological treatment (e.g. start of Long-term oxygen therapy (LTOT), new listing for lung transplantation, physiotherapy) for Idiopathic Pulmonary Fibrosis (IPF) by study visit is reported. The categories of non-pharmacological treatment for Idiopathic Pulmonary Fibrosis (IPF) are the following: * No * Yes * Unknown * Missing
Time frame: At baseline visit and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit.
Population: Full Analysis Set (FAS) comprised all subjects enrolled in the study with at least one measurement of any of the primary endpoints during the study. This population was used to run any statistics of the study.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 3 months | Yes | 13 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 3 months | Missing | 10 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | Baseline | Yes | 13 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | Baseline | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | Baseline | Missing | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 3 months | No | 70 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | Baseline | No | 83 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 3 months | Unknown | 3 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 6 months | No | 67 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 6 months | Yes | 11 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 6 months | Unknown | 2 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 6 months | Missing | 16 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 12 months | No | 66 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 12 months | Yes | 10 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 12 months | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 12 months | Missing | 20 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 18 months | No | 61 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 18 months | Yes | 10 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 18 months | Unknown | 2 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 18 months | Missing | 23 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 24 months | No | 55 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 24 months | Yes | 9 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 24 months | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 24 months | Missing | 32 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 24 months | Unknown | 2 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 3 months | Unknown | 1 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 12 months | No | 116 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | Baseline | No | 162 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 18 months | Unknown | 2 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | Baseline | Yes | 43 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 12 months | Yes | 38 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | Baseline | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 24 months | Yes | 27 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | Baseline | Missing | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 12 months | Unknown | 7 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 3 months | No | 137 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 18 months | Missing | 65 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 3 months | Yes | 37 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 12 months | Missing | 44 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 3 months | Missing | 30 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 24 months | Missing | 80 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 6 months | No | 127 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 18 months | No | 109 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 6 months | Yes | 35 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 24 months | No | 96 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 6 months | Unknown | 7 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 18 months | Yes | 29 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 6 months | Missing | 36 Participants |
Primary
Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit
Number of patients in each category of physician's clinical assessment of the probable course of IPF by study visit is reported. Physician's clinical rating of the probable course of IPF (stable, slow or rapid progression) was based on available Forced vital capacity (FVC) results, diffusion capacity for carbon monoxide (DLCO) results, physical examination, hospitalizations/events between the visits. The categories of physician's clinical assessment are the following: * Stable disease * Slow progression * Rapid progression * No judgement possible * Missing
Time frame: At baseline (up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit.
Population: Full Analysis Set (FAS) comprised all subjects enrolled in the study with at least one measurement of any of the primary endpoints during the study. This population was used to run any statistics of the study. Only participants with non-missing results are reported.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | Baseline (up to 12 months prior to baseline visit) | Stable disease | 79 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 6 months (since last visit) | Missing | 16 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 18 months (since last visit) | Slow progression | 6 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 24 months (since last visit) | Slow progression | 10 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | Baseline (up to 12 months prior to baseline visit) | Slow progression | 13 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | Baseline (up to 12 months prior to baseline visit) | Rapid progression | 2 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | Baseline (up to 12 months prior to baseline visit) | No judgement possible | 2 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | Baseline (up to 12 months prior to baseline visit) | Missing | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 3 months (since last visit) | Stable disease | 75 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 3 months (since last visit) | Slow progression | 7 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 3 months (since last visit) | Rapid progression | 3 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 3 months (since last visit) | No judgement possible | 1 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 3 months (since last visit) | Missing | 10 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 6 months (since last visit) | Stable disease | 71 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 6 months (since last visit) | Slow progression | 4 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 6 months (since last visit) | Rapid progression | 5 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 6 months (since last visit) | No judgement possible | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 12 months (since last visit) | Stable disease | 64 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 12 months (since last visit) | Slow progression | 10 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 12 months (since last visit) | Rapid progression | 2 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 12 months (since last visit) | No judgement possible | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 12 months (since last visit) | Missing | 20 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 18 months (since last visit) | Stable disease | 63 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 18 months (since last visit) | Rapid progression | 4 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 18 months (since last visit) | No judgement possible | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 18 months (since last visit) | Missing | 23 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 24 months (since last visit) | Stable disease | 50 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 24 months (since last visit) | Rapid progression | 4 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 24 months (since last visit) | No judgement possible | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 24 months (since last visit) | Missing | 32 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 24 months (since last visit) | Stable disease | 100 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 6 months (since last visit) | No judgement possible | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 6 months (since last visit) | Missing | 36 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 18 months (since last visit) | Rapid progression | 5 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 24 months (since last visit) | Slow progression | 21 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | Baseline (up to 12 months prior to baseline visit) | Stable disease | 158 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 12 months (since last visit) | Stable disease | 134 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | Baseline (up to 12 months prior to baseline visit) | Slow progression | 41 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 24 months (since last visit) | No judgement possible | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | Baseline (up to 12 months prior to baseline visit) | Rapid progression | 3 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 12 months (since last visit) | Slow progression | 22 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | Baseline (up to 12 months prior to baseline visit) | No judgement possible | 3 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 18 months (since last visit) | No judgement possible | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | Baseline (up to 12 months prior to baseline visit) | Missing | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 12 months (since last visit) | Rapid progression | 3 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 3 months (since last visit) | Stable disease | 156 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 24 months (since last visit) | Rapid progression | 4 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 3 months (since last visit) | Slow progression | 16 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 12 months (since last visit) | No judgement possible | 2 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 3 months (since last visit) | Rapid progression | 3 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 18 months (since last visit) | Missing | 66 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 3 months (since last visit) | No judgement possible | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 12 months (since last visit) | Missing | 44 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 3 months (since last visit) | Missing | 30 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 24 months (since last visit) | Missing | 80 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 6 months (since last visit) | Stable disease | 140 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 18 months (since last visit) | Stable disease | 113 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 6 months (since last visit) | Slow progression | 23 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 18 months (since last visit) | Slow progression | 21 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit | 6 months (since last visit) | Rapid progression | 6 Participants |
Primary
Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib
Number of patients in each category with usage of pirfenidone and nintedanib is reported. The categories for usage of pirfenidone and nintedanib are the following: * Yes * No * Unknown * Missing
Time frame: From signing the informed consent onwards until the end of the study, up to 24 months.
Population: Full Analysis Set (FAS) comprised all subjects enrolled in the study with at least one measurement of any of the primary endpoints during the study. This population was used to run any statistics of the study.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib | Nintedanib | Yes | 45 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib | Pirfenidone | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib | Nintedanib | No | 41 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib | Pirfenidone | No | 54 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib | Nintedanib | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib | Pirfenidone | Missing | 9 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib | Nintedanib | Missing | 10 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib | Pirfenidone | Yes | 33 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib | Nintedanib | Missing | 8 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib | Pirfenidone | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib | Pirfenidone | Yes | 87 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib | Pirfenidone | Missing | 4 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib | Nintedanib | Yes | 81 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib | Nintedanib | No | 116 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib | Nintedanib | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib | Pirfenidone | No | 114 Participants |
Primary
Number of Physician Contacts Per Patient by Study Visit
Number of physician contacts per patient is reported. For the baseline visit mean and standard deviation of physician contacts with the patient up to 12 months prior to baseline visit is reported. For the study visits at 3 months, at 6 months, at 12 months, at 18 months and at 24 months mean and standard deviation of physician contacts with the patient since the last study visit is reported.
Time frame: At baseline (up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit.
Population: Full Analysis Set (FAS) comprised all subjects enrolled in the study with at least one measurement of any of the primary endpoints during the study. This population was used to run any statistics of the study. Only participants with non-missing results are reported.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| IPF Patients With Less Than 6 Months Diagnosis | Number of Physician Contacts Per Patient by Study Visit | Baseline (up to 12 months prior to baseline visit) | 3.651 physician contacts per patient | Standard Deviation 2.506 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Physician Contacts Per Patient by Study Visit | 3 months (since last visit) | 0.801 physician contacts per patient | Standard Deviation 1.033 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Physician Contacts Per Patient by Study Visit | 6 months (since last visit) | 0.676 physician contacts per patient | Standard Deviation 0.832 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Physician Contacts Per Patient by Study Visit | 12 months (since last visit) | 1.105 physician contacts per patient | Standard Deviation 1.406 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Physician Contacts Per Patient by Study Visit | 18 months (since last visit) | 0.778 physician contacts per patient | Standard Deviation 0.985 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Physician Contacts Per Patient by Study Visit | 24 months (since last visit) | 0.553 physician contacts per patient | Standard Deviation 0.842 |
Primary
Number of Visits in Other Physicians Than the Pulmonologists by Study Visit
Number of visits in other physicians than the pulmonologists by study visit is reported. For the baseline visit mean and standard deviation of visits in other physicians than the pulmonologists up to 12 months prior to baseline visit is reported. For the study visits at 3 months, at 6 months, at 12 months, at 18 months and at 24 months mean and standard deviation of visits in other physicians than the pulmonologists since the last study visit is reported.
Time frame: At baseline (up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit.
Population: Full Analysis Set (FAS) comprised all subjects enrolled in the study with at least one measurement of any of the primary endpoints during the study. This population was used to run any statistics of the study. Only participants with non-missing results are reported.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| IPF Patients With Less Than 6 Months Diagnosis | Number of Visits in Other Physicians Than the Pulmonologists by Study Visit | Baseline (up to 12 months prior to baseline visit) | 1.056 visits per patient | Standard Deviation 2.012 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Visits in Other Physicians Than the Pulmonologists by Study Visit | 3 months (since last visit) | 0.34 visits per patient | Standard Deviation 0.626 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Visits in Other Physicians Than the Pulmonologists by Study Visit | 6 months (since last visit) | 0.358 visits per patient | Standard Deviation 0.749 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Visits in Other Physicians Than the Pulmonologists by Study Visit | 12 months (since last visit) | 0.561 visits per patient | Standard Deviation 0.979 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Visits in Other Physicians Than the Pulmonologists by Study Visit | 18 months (since last visit) | 0.588 visits per patient | Standard Deviation 1.098 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Visits in Other Physicians Than the Pulmonologists by Study Visit | 24 months (since last visit) | 0.505 visits per patient | Standard Deviation 0.831 |
Primary
Number of Visits in Outpatient Department by Study Visit
Number of visits in outpatient department by study visit is reported. For the baseline visit mean and standard deviation of visits in outpatient department up to 12 months prior to baseline visit is reported. For the study visits at 3 months, at 6 months, at 12 months, at 18 months and at 24 months mean and standard deviation of visits in outpatient department since the last study visit is reported.
Time frame: At baseline (up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit.
Population: Full Analysis Set (FAS) comprised all subjects enrolled in the study with at least one measurement of any of the primary endpoints during the study. This population was used to run any statistics of the study. Only participants with non-missing results are reported.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| IPF Patients With Less Than 6 Months Diagnosis | Number of Visits in Outpatient Department by Study Visit | Baseline (up to 12 months prior to baseline visit) | 2.844 visits per patient | Standard Deviation 3.042 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Visits in Outpatient Department by Study Visit | 3 months (since last visit) | 0.545 visits per patient | Standard Deviation 0.899 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Visits in Outpatient Department by Study Visit | 6 months (since last visit) | 0.502 visits per patient | Standard Deviation 0.852 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Visits in Outpatient Department by Study Visit | 12 months (since last visit) | 0.856 visits per patient | Standard Deviation 1.358 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Visits in Outpatient Department by Study Visit | 18 months (since last visit) | 0.664 visits per patient | Standard Deviation 1.217 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Visits in Outpatient Department by Study Visit | 24 months (since last visit) | 0.489 visits per patient | Standard Deviation 0.939 |
Primary
Number of Visits in Pulmonologists by Study Visit
Number of visits in pulmonologists by study visit is reported. For the baseline visit mean and standard deviation of visits in pulmonologists up to 12 months prior to baseline visit is reported. For the study visits at 3 months, at 6 months, at 12 months, at 18 months and at 24 months mean and standard deviation of visits in pulmonologists since the last study visit is reported.
Time frame: At baseline (up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit.
Population: Full Analysis Set (FAS) comprised all subjects enrolled in the study with at least one measurement of any of the primary endpoints during the study. This population was used to run any statistics of the study. Only participants with non-missing results are reported.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| IPF Patients With Less Than 6 Months Diagnosis | Number of Visits in Pulmonologists by Study Visit | 18 months (since last visit) | 0.698 visits per patient | Standard Deviation 1.05 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Visits in Pulmonologists by Study Visit | Baseline (up to 12 months prior to baseline visit) | 3.027 visits per patient | Standard Deviation 2.209 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Visits in Pulmonologists by Study Visit | 3 months (since last visit) | 0.654 visits per patient | Standard Deviation 0.839 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Visits in Pulmonologists by Study Visit | 6 months (since last visit) | 0.624 visits per patient | Standard Deviation 0.777 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Visits in Pulmonologists by Study Visit | 12 months (since last visit) | 0.928 visits per patient | Standard Deviation 1.171 |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Visits in Pulmonologists by Study Visit | 24 months (since last visit) | 0.479 visits per patient | Standard Deviation 0.749 |
Secondary
Number of Patients in Each Category of Concomitant Medications
Concomitant medication was defined as any treatment presented following the Informed Consent Form (ICF) signature. If stop date was missing in the electronic Case Report Form (eCRF), medication was considered as concomitant. The number of patients in each category of the following concomitant medications is reported. The concomitant medications are: * Corticosteroids * N-Acetylcysteine * Azathioprine * Cyclophosphamide * Cyclosporine A * Other immuno-suppressant * Anticoagulants * Gastroesophageal reflux disease (GERD) medication * Phosphodiesterase type 5 (PDE-5) inhibitor * Endothelin receptor antagonist * Non-steroidal anti-inflammatory drugs (NSAIDs) other than aspirin * Hormonal contraceptives * Hormone replacement therapy * Anti-vascular endothelial growth factor (VEGF) drugs * Other (other than listed above) The categories for each concomitant medication listed above are the following: * Yes * No * Unknown * Missing
Time frame: From signing the informed consent onwards until the end of the study, up to 24 months.
Population: Full Analysis Set (FAS) comprised all subjects enrolled in the study with at least one measurement of any of the primary endpoints during the study. This population was used to run any statistics of the study.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Anticoagulants | Missing | 9 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Azathioprine | Missing | 12 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | GERD medication | Yes | 28 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | GERD medication | No | 57 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Anti-VEGF drugs | Yes | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | GERD medication | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Cyclophosphamide | Yes | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | N-Acetylcysteine | Yes | 1 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | PDE-5 inhibitor | Yes | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Cyclophosphamide | No | 84 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | PDE-5 inhibitor | No | 83 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Corticosteroids | Yes | 11 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | PDE-5 inhibitor | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Cyclophosphamide | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | PDE-5 inhibitor | Missing | 13 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | N-Acetylcysteine | No | 83 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Hormone replacement therapy | Missing | 13 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Cyclophosphamide | Missing | 12 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Endothelin receptor antagonist | No | 84 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Endothelin receptor antagonist | Yes | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Endothelin receptor antagonist | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Cyclosporine A | Yes | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Endothelin receptor antagonist | Missing | 12 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | N-Acetylcysteine | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | NSAIDs other than aspirin | Yes | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Cyclosporine A | No | 84 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | NSAIDs other than aspirin | No | 84 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Corticosteroids | No | 73 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | NSAIDs other than aspirin | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Cyclosporine A | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | NSAIDs other than aspirin | Missing | 12 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | N-Acetylcysteine | Missing | 12 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Hormonal contraceptives | Yes | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Cyclosporine A | Missing | 12 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Hormonal contraceptives | No | 83 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Hormone replacement therapy | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Hormonal contraceptives | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Other immuno-suppressant | Yes | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Hormonal contraceptives | Missing | 13 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Other immuno-suppressant | No | 81 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Hormone replacement therapy | Yes | 2 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Azathioprine | Yes | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Hormone replacement therapy | No | 81 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Other immuno-suppressant | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Corticosteroids | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Other immuno-suppressant | Missing | 15 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Anti-VEGF drugs | No | 83 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Azathioprine | No | 84 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Anti-VEGF drugs | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Anticoagulants | Yes | 34 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Anti-VEGF drugs | Missing | 13 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | GERD medication | Missing | 11 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Other | Yes | 85 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Anticoagulants | No | 53 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Other | No | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Azathioprine | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Other | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Anticoagulants | Unknown | 0 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Other | Missing | 11 Participants |
| IPF Patients With Less Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Corticosteroids | Missing | 12 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Other | Missing | 29 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | GERD medication | Yes | 84 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Hormone replacement therapy | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Corticosteroids | Yes | 21 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Corticosteroids | No | 175 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Corticosteroids | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Corticosteroids | Missing | 9 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | N-Acetylcysteine | Yes | 3 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | N-Acetylcysteine | No | 194 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | N-Acetylcysteine | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | N-Acetylcysteine | Missing | 8 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Azathioprine | Yes | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Azathioprine | No | 197 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Azathioprine | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Azathioprine | Missing | 8 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Cyclophosphamide | Yes | 1 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Cyclophosphamide | No | 195 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Cyclophosphamide | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Cyclophosphamide | Missing | 9 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Cyclosporine A | Yes | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Cyclosporine A | No | 195 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Cyclosporine A | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Cyclosporine A | Missing | 10 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Other immuno-suppressant | No | 189 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Other immuno-suppressant | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Other immuno-suppressant | Missing | 12 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Anticoagulants | Yes | 67 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Anticoagulants | No | 129 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Anticoagulants | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Anticoagulants | Missing | 9 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | GERD medication | No | 110 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | GERD medication | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | GERD medication | Missing | 11 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | PDE-5 inhibitor | Yes | 5 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | PDE-5 inhibitor | No | 189 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | PDE-5 inhibitor | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | PDE-5 inhibitor | Missing | 11 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Endothelin receptor antagonist | Yes | 2 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Endothelin receptor antagonist | No | 192 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Endothelin receptor antagonist | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Endothelin receptor antagonist | Missing | 11 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | NSAIDs other than aspirin | Yes | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | NSAIDs other than aspirin | No | 194 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | NSAIDs other than aspirin | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | NSAIDs other than aspirin | Missing | 11 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Hormonal contraceptives | Yes | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Hormonal contraceptives | No | 192 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Hormonal contraceptives | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Hormonal contraceptives | Missing | 13 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Hormone replacement therapy | Yes | 2 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Hormone replacement therapy | No | 188 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Hormone replacement therapy | Missing | 15 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Anti-VEGF drugs | Yes | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Anti-VEGF drugs | No | 192 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Anti-VEGF drugs | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Anti-VEGF drugs | Missing | 13 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Other | Yes | 176 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Other | No | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Other | Unknown | 0 Participants |
| IPF Patients With Equal or More Than 6 Months Diagnosis | Number of Patients in Each Category of Concomitant Medications | Other immuno-suppressant | Yes | 4 Participants |